On March 9, 2021, the National Comprehensive Cancer Network (NCCN) released an update to its clinical practice guideline for esophageal and esophageal junction cancers.
In the section labeled principles of systemic therapy for unresectable locally advanced, recurrent or metastatic disease, under second-line or subsequent therapy, fam-trastuzumab deruxtecan-nxki was added as a category 2A recommendation for HER2-positive adenocarcinoma.
In the section labeled principles of systemic therapy regimens and dosing schedules, the dosing for fluorouracil and irinotecan was updated by removing “only for adenocarcinoma.” Dosing for fam-trastuzumab deruxtecan-nxki was added. Lastly, the dosing schedule for paclitaxel was revised to 80 mg/m2 IV weekly, cycled every 28 days.—Janelle Bradley
